Given the necessity to elongate telomeres for tumorigenesis, we hypothesized that the remaining 87.7% of sarcoma samples need to have either acquired mutations in other genes leading to ALT or activated non-ALT-mediated mechanisms of telomere lengthening. The gene discussed is GPT; the disease is sarcoma.